Connect Biopharma Files 8-K on Agreements and Equity Sales

TL;DR

CNTB filed an 8-K detailing new deals and stock sales. Keep an eye on this.

AI Summary

Connect Biopharma Holdings Ltd. filed an 8-K on March 30, 2026, disclosing the entry into a material definitive agreement and unregistered sales of equity securities. The filing also includes Regulation FD disclosures, other events, and financial statements and exhibits. Specific details regarding the agreements and sales are provided in the attached exhibits.

Why It Matters

This filing indicates significant corporate actions, including new agreements and the issuance of equity, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.

Key Players & Entities

• Connect Biopharma Holdings Ltd (company) — Filer of the 8-K report
• 0001835268 (company) — CIK number for Connect Biopharma Holdings Ltd
• 2026-03-30 (date) — Filing date of the 8-K
• 2026-03-29 (date) — Period of report for the 8-K

FAQ

Key Financial Figures

• $0.000174 — registered Ordinary Shares, par value $0.000174 per Share CNTB The Nasdaq Global Market
• $3.25 — (the "Ordinary Shares"), at a price of $3.25 per Share with respect to any Purchaser
• $20.2 m — cement are expected to be approximately $20.2 million, before deducting offering fees a

Filing Documents

• cntb-20260329.htm (8-K) — 42KB
• exhibit101-securitiespurch.htm (EX-10.1) — 327KB
• exhibit991-phase1ivstudypr.htm (EX-99.1) — 24KB
• exhibit992-radiantadstudyp.htm (EX-99.2) — 25KB
• exhibit993-pipepressrelease.htm (EX-99.3) — 12KB
• image_0a.jpg (GRAPHIC) — 0KB
• image_1a.jpg (GRAPHIC) — 0KB
• 0001835268-26-000006.txt ( ) — 638KB
• cntb-20260329.xsd (EX-101.SCH) — 2KB
• cntb-20260329_lab.xml (EX-101.LAB) — 22KB
• cntb-20260329_pre.xml (EX-101.PRE) — 13KB
• cntb-20260329_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On March 29, 2026, Connect Biopharma Holdings Limited (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with the purchasers named therein (the "Purchasers"), for the private placement (the "Private Placement") of 6,130,000 shares (the "Shares") of the Company's ordinary shares, par value $0.000174 per share (the "Ordinary Shares"), at a price of $3.25 per Share with respect to any Purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company. The aggregate gross proceeds for the Private Placement are expected to be approximately $20.2 million, before deducting offering fees and expenses. The Private Placement is expected to close on March 31, 2026, subject to customary closing conditions. The Private Placement is being conducted in accordance with applicable Nasdaq rules. Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint placement agents for the Private Placement. The Company expects to use the net proceeds from the Private Placement to fund the research and development of its clinical-stage product candidates and other development programs and for working capital and other general corporate purposes. The Company estimates, based on its current operating plan, that the net proceeds from the Private Placement, together with its current cash, cash equivalents and short-term investments, will be sufficient to fund its operations into the second half of 2027. Pursuant to the Purchase Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") within 45 days after the closing of the Private Placement (subject to certain exceptions) for purposes of registering the resale of the Shares, to use its reasonable best efforts to have such registration statement declared effective within the time period set forth in the Purchase Agreement, and to kee

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The disclosures set forth in Item 1.01 above are incorporated by reference into this Item 3.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 30, 2026, the Company issued a press release announcing topline preliminary results for its Phase 1 clinical pharmacology study evaluating intravenous ("IV") rademikibart. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. On March 30, 2026, the Company issued a press release announcing results from a Phase 3 52-week study in patients with moderate-to-severe atopic dermatitis ("AD") conducted by the Company's partner in China, Simcere Pharmaceutical Co., Ltd. ("Simcere"). A copy of the press release is attached as Exhibit 99.2 and is incorporated herein by reference. On March 30, 2026, the Company issued a press release announcing that it has entered into the Purchase Agreement. A copy of the press release is attached as Exhibit 99.3 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On March 30, 2026, the Company issued a press release announcing topline preliminary results for its Phase 1 clinical pharmacology study evaluating IV rademikibart. On March 30, 2026, the Company announced results from a Phase 3 52-week study in patients with moderate-to-severe AD conducted by Simcere.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Securities Purchase Agreement, dated March 29, 2026, by and between Connect Biopharma Holdings Limited and each of the purchasers party thereto 99.1 Press Release of the Company, dated March 30, 2026 99.2 Press Release of the Company, dated March 30, 2026 99.3 Press Release of the Company, dated March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements The Company cautions you that statements contained in this Current Report on Form 8-K, including in the press releases filed herewith as Exhibits 99.1, 99.2 and 99.3, regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the timing, size and expectation of the closing of the Private Placement; expectations regarding market conditions, the satisfaction of customary closing conditions related to the Private Placement, and the anticipated use of proceeds therefrom; the anticipated filing of a registration statement to cover the resale of Shares; the Company's expectation that its current cash, cash equivalents, and short-term investments will fund our operations into the second half of 2027; prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience); planned or expected product approval applications or approvals; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we or our current or future partners will need expanded or additional trials in order to obtain regulatory approval for our product candidates; the timing of when we expect to report data from our clinical trials; whether Simcere's pending New Drug Application for rademikibart in China will receive approval by the National Medical Products Administration, and the timing of any such approval; the timing and results of any planned interactions with the FDA; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People's Republic of China, Europe and other jurisdic

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CONNECT BIOPHARMA HOLDINGS LIMITED Date: March 30, 2026 By: /s/ David Szekeres Name: David Szekeres Title: President

View Full Filing

View this 8-K filing on SEC EDGAR